Skip to content

The influence of inflammation on surgery of the male and female urinary tract system and male reproductive organs

The role of inflammation in urological surgery

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ISRCTN
Registry ID
ISRCTN55335030
Enrollment
500
Registered
2022-03-31
Start date
2021-10-08
Completion date
Unknown
Last updated
2022-04-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Urological surgery procedures Surgery

Interventions

According to EAU guidelines and pre-hospitalization protocols, all eligible patients will undergo the following clinical/instrumental assessments: • Historical and physical examination

Sponsors

European Urological Center C.Ur.E SRL/STP
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Patients older than 18 undergoing the following urological surgery procedures: 1. Radical caste Tommy 2. Surgery for benign prostatic obstruction 3. Radical and partial nephrectomy 4. Radical nephroureterectomy 5. Radical prostatectomy 6. Ureterolithotripsy 7. Orchifunicolectomy

Exclusion criteria

Exclusion criteria: Patients who, due to age or clinical condition, are unable to receive the information and to sign the informed consent

Design outcomes

Primary

MeasureTime frame
Inflammation indexes will be calculated by the neutrophils/lymphocytes, neutrophils/monocytes, lymphocytes/platelets, CPR, PCT, Albumin, fibrinogen, modified Glasgow prognostic score (mGPS) measured at the time of surgery and at post-operative evaluations using blood and urine samples

Secondary

MeasureTime frame
Obtained by review of medical records at baseline and at follow up appointments: 1. Lifestyles, physical activity and metabolic syndrome measured using: smoker status, BMI, hypertension, diabetes, dyslipdemia, COPD, ECOG, NYHA. 2. Frailty index measured using; questionnaire G8; sFI calculated including the precence of diabetes, functional status of patient before surgery, COPD, heart failure, hypertension; Charlson Comorbidity index. 3. Disease progression, disease-free survival, in patients with cancer of the urogenital system 4. measured using: overall survival (months) and recurrence free survival (months) 5. Histological characteristics of urogenital cancers measured using histopathological reports. 6. Histological inflammation measured using histopathological reports. 7. Main urodynamic parameters in patients undergoing benign prostatic obstruction surgery 8. measured using Uroflowmetry maximum urinary flow (Qmax), voided volume and post void residual 9. Functional recovery after urological surgery (assessed as sexual activity, ejaculation disorders, infertility and urinary incontinence) measured using IPSS, PUF, NIH-CPSI, IIEF questionnaires.

Countries

Italy

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026